Deals channel feed

Boehringer In­gel­heim taps a pop­u­lar an­ti­body dis­cov­ery play­er for ac­cess to drug 'li­brary of li­braries'

4 years ago

Io­n­is col­lab­o­ra­tor Flamin­go is ready to take flight with 3 an­ti­sense drugs in the clin­ic and mys­te­ri­ous RNA in its sights

4 years ago
Startups

Eli Lil­ly bets on an RNA base edit­ing out­fit lever­ag­ing the body's own en­zymes to re­verse mu­ta­tions

4 years ago
Discovery

Months af­ter land­ing Cana­di­an site from gov­ern­ment, Re­silience an­nounces a big mR­NA part­ner

4 years ago
Manufacturing

Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

4 years ago

Mer­ck KGaA en­trusts se­cre­tive start­up with a mid-stage can­cer drug tar­get­ing mas­ter sig­nal­ing path­way

4 years ago

Years af­ter Pfiz­er passed on a buy­out op­tion, AM-Phar­ma finds a new part­ner for its kid­ney drug

4 years ago

Mov­ing on from a ma­jor set­back, Roche lines up a new Hunt­ing­ton's pro­gram for gene ther­a­py sub Spark

4 years ago
R&D

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

4 years ago
Cell/Gene Tx

Pri­vate eq­ui­ty, sov­er­eign wealth fund al­ly on an $8B buy­out aimed at tak­ing rare dis­ease play­er pri­vate

4 years ago

An FTC re­view of the Sanofi/Trans­late merg­er has a new dead­line af­ter agency calls for more time

4 years ago
Pharma

An­tivi­ral nasal drop mak­er does the Nas­daq shuf­fle as part of mi­nor SPAC re­verse merg­er

4 years ago
Financing

Lu­ca Santarel­li's Vec­tivBio buys out small Mass­a­chu­setts biotech, re­dou­bling fo­cus on meta­bol­ic dis­ease

4 years ago

Play­ing a sur­pris­ing­ly hot hand, Be­yond­Spring nails a $200M Chi­na deal in wake of a piv­otal suc­cess

4 years ago
China

ADC Ther­a­peu­tics sells off roy­al­ty share for lead an­ti­body-drug con­ju­gate in $325M deal

4 years ago

Al­bert Bourla picks a new deal­mak­er to lead the hunt for more drugs to swell Pfiz­er’s pipeline

4 years ago
R&D

Eli Lil­ly keeps its foot on deal­mak­ing ped­al, re­cruit­ing Car­olyn Bertozzi's pro­tein degra­da­tion tech for $1.6B+

4 years ago

Ex­clu­sive: Roche tees up $3B+ for Shape's RNA edit­ing plat­form, with the bold promise of 'one-time' cures for Alzheimer's, Parkin­son's

4 years ago

Ver­tex goes back to gene-edit­ing part­ner — and sci­ence founder Feng Zhang — to add $1.2B deal on en­gi­neered cell ther­a­pies

4 years ago

Genevant scores with Take­da again as LNPs con­tin­ue to at­tract in­ter­est for RNA ther­a­py

4 years ago

Pfiz­er doles out $2.3B for blood can­cer play­er to flesh out its end-of-decade on­col­o­gy port­fo­lio

4 years ago

What an­titrust chal­lenge? Il­lu­mi­na com­pletes $8B Grail buy­out while FTC, EU probes re­main on­go­ing

4 years ago
Pharma

Ver­i­ly scoops up a fel­low soft­ware mak­er as Amy Aber­nethy scales its clin­i­cal tri­als plat­form

4 years ago
Outsourcing

In­no­Care bags Chi­nese rights to In­cyte CAR-T ri­val Mon­ju­vi in bid to ex­pand in-house pipeline

4 years ago
China
First page Previous page 71727374757677 Next page Last page
A service from the Financial Times